Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CET
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
08:06a CVS HEALTH : to close 11 Chicago stores by late March
02/24 CVS HEALTH : And Breathe California Announce Statewide Finalists In Student Film..
02/22 CVS HEALTH : Pharmacy Is First National Retail Pharmacy to Remove Artificial Tra..
02/20 CVS HEALTH : president says big changes underway in pharmacy
02/17 IT HAS WORKED : CVS Health Corp (NYSE:CVS) Says Of Its Exit Of Cigarette Busines..
02/17 CVS : Restricting Access to Cigarettes can positively Impact Public Health
02/17 CVS HEALTH : Maintaining Quality and Improving Outcomes during Care Transitions
02/17 CVS HEALTH : FORTUNE Recognizes CVS Health on List of 'World's Most Admired Comp..
02/16 CVS HEALTH : Research Institute Study Confirms that the Company's Tobacco Remova..
02/16 CVS HEALTH : FORTUNE Recognizes CVS Health on List of "World's Most Admired Comp..
More news
Sector news : Drug Retailers - NEC
02/16DJRetail CEOs Meet With Trump Over Border Tax Concerns -- Update
02/15DJRetail CEOs Meet With Trump Over Border Tax Concerns
02/14DJEXPRESS SCRIPTS : Revenue Falls
02/14 Exclusive - Trump to meet with retail CEOs on taxes, infrastructure
02/09DJCVS HEALTH : Profit Rises, Helped by Pharmacy Strength -- Update
More sector news : Drug Retailers - NEC
News from SeekingAlpha
02/24 Rite Aid Investors Should Take A Hard Look The Walgreens Merger Valuation Bef..
02/24 Is It Time To Sell Everything But High Quality Stocks?
02/23 Tracking Wallace Weitz's Weitz Investment Management Portfolio - Q4 2016 Upda..
02/23 Can 20 Financial Ratios Measure A Company's Moat Just Like Morningstar? Updat..
02/17 Tracking George Soros's Portfolio - Q4 2016 Update
Advertisement
Financials ($)
Sales 2017 184 356 M
EBIT 2017 10 398 M
Net income 2017 5 637 M
Debt 2017 24 997 M
Yield 2017 2,35%
P/E ratio 2017 15,40
P/E ratio 2018 13,79
EV / Sales 2017 0,59x
EV / Sales 2018 0,56x
Capitalization 83 574 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,3 $
Spread / Average Target 6,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP2.47%83 574
WALGREENS BOOTS ALLIAN..5.11%94 567
EXPRESS SCRIPTS HOLDIN..3.11%43 339
MCKESSON CORPORATION6.07%31 988
CARDINAL HEALTH INC13.56%25 911
AMERISOURCEBERGEN CORP..17.16%20 024
More Results